Medicinova (MNOV) Liabilities and Shareholders Equity (2010 - 2025)

Medicinova (MNOV) has 16 years of Liabilities and Shareholders Equity data on file, last reported at $45.6 million in Q4 2025.

• On a quarterly basis, Liabilities and Shareholders Equity fell 18.39% year-over-year to $45.6 million in Q4 2025; TTM through Dec 2025 was $195.4 million, a 17.64% decrease from a year earlier, with the FY2025 full-year figure at $45.6 million, down 18.39% from the prior year.
• Liabilities and Shareholders Equity for Q4 2025 stood at $45.6 million, down from $47.6 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for MNOV reached as high as $96.1 million in Q1 2021 and fell as low as $45.6 million in Q4 2025.
• Historically, Liabilities and Shareholders Equity has averaged $69.7 million across 5 years, with a median of $68.4 million in 2023.
• Across the five-year window, Liabilities and Shareholders Equity increased 24.78% in 2021 and retreated 18.39% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $87.4 million in 2021, then fell by 15.16% to $74.2 million in 2022, then retreated by 10.63% to $66.3 million in 2023, then retreated by 15.68% to $55.9 million in 2024, then declined by 18.39% to $45.6 million in 2025.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $45.6 million in Q4 2025, $47.6 million in Q3 2025, and $49.8 million in Q2 2025.